Clinical Trial

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in participants with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.
Protocol Amendment History 9 changes
notable Trial sites expanded: 60 -> 64 locations 2026-08-11
notable Trial sites expanded: 57 -> 60 locations 2026-08-04
notable Trial sites expanded: 42 -> 47 locations 2026-07-02
notable Trial sites expanded: 35 -> 39 locations 2026-06-26
notable Trial sites expanded: 32 -> 35 locations 2026-06-25
notable Trial sites expanded: 29 -> 32 locations 2026-06-24
notable Trial sites expanded: 22 -> 25 locations 2026-06-16
notable Trial sites expanded: 11 -> 14 locations 2026-06-02
notable Trial sites expanded: 2 -> 11 locations 2026-05-23
Trial Details
NCT Number NCT07284459
Lead Sponsor Contineum Therapeutics
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 324 participants
Start Date 2026-01-08
Primary Completion 2028-05 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-10